In PPMI, most individuals with clinically diagnosed early PD met criteria for stage 3 (65% sporadic PD, 61% LRRK2 PD, and 59% GBA PD); similarly, 66% PASADENA and 55% SPARK participants were stage 3. The gene discussed is LRRK2; the disease is Parkinson disease.